Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by robertshawon Nov 30, 2022 8:08pm
170 Views
Post# 35141571

RE:RE:what we don't know about the clinical data

RE:RE:what we don't know about the clinical data
FGPstock wrote:
DJD, how can you expect the stock you go up. they burried material information about the trial and their plans in the "interim financial statement". Other than ppl on stockhouse and ceo probably even red the NR. So, either your right, they are bad are marketing or don't want to advertise the success of the trial until they get their golden parachutes set...

Quite right. They are bad at marketing this technology.

If they are smart, they should contact with the FDA to get AA approval 1st, as the results are far better than that of Keytruda's (with less than half of patients in the trial of Keytruda).

So, in stead of waiting for the 25th patients of the 450-days data, they should force FDA to issue the AA approval 1st.

In this way, they can thus force Blowjobjoe's bosses to cover all of the historical naked shorted shares.

But as I said before, I doubt the management has that wit to do so. 
<< Previous
Bullboard Posts
Next >>